Cubist completes Phase III Cidecin trial

CBST completed enrollment of 729 patients in its first Phase III study of Cidecin daptomycin to treat community-acquired pneumonia requiring hospitalization. The trial, CAP1, compares 4 mg/kg of Cidecin given once daily to 2g once daily of Rocephin ceftriaxone. The primary endpoint of the double-blind study in the Northern Hemisphere is resolution of signs and symptoms (clinical efficacy), and secondary endpoints include bacteriological efficacy and duration of intravenous therapy. Data from the trial are expected in the first half of 2002. Completion of CAP1 triggers a $3 million milestone to CBST from partner Gilead (GILD) under the companies' European marketing deal. ...